CELLSEARCHTM was the first and only FDA-approved assay to date for CTC quantitation by enriching for EpCAM-positive cells in the monitoring of patients with advanced breast, colorectal, and metastatic prostate cancer (Table 1). The gene discussed is EPCAM; the disease is metastatic prostate carcinoma.